PLOS ONE

An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease

Sara Majd Jabbari[1], Khadije Maajani[2], Shahin Merat[3], Hossein Poustchi[3], Sadaf G. Sepanlou[1] *

1 Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran, 2 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran, 3 Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran

* sepanlou@yahoo.com, sgsepanlou@tums.ac.ir

Abstract

Sofosbuvir seems to be a revolutionary treatment for Hepatitis C-infected patients with advanced chronic kidney disease (CKD) but existing evidence is not quite adequate. The aim of this study was to evaluate the efficacy and safety of Sofosbuvir-based therapy without Ribavirin for all hepatitis C virus genotypes among patients with advanced CKD. We conducted an updated systematic literature search from the beginning of 2013 up to June 2020. Sustained virologic response (SVR) rate at 12 and/or 24 weeks after the end of treatment, and adverse events in HCV-infected patients with advanced CKD were pooled using random effects models. We included 27 published articles in our meta-analyses, totaling 1,464 HCV-infected patients with advanced CKD. We found a substantial heterogeneity based on the I^2 index (P = 0.00, I^2 = 56.1%). The pooled SVR rates at 12 and 24 weeks after the end of Sofosbuvir-based treatment were 97% (95% Confidence Interval: 95–99) and 95% (89–99) respectively. The pooled SVR12 rates were 98% (96–100) and 94% (90–97) in patients under 60 and over 60 years old respectively. The pooled incidence of severe adverse events was 0.11 (0.04–0.19). The pooled SVR12 rate after completion of the half dose regimen was as high as the full dose treatment but it was associated with less adverse events (0.06 versus 0.14). The pooled SVR12 rate was 98% (91–100) in cirrhotic patients and 100% (98–100) in non-cirrhotic patients. The endorsement of Sofosbuvir-based regimen can improve the treatment of hepatitis C virus infection in patients with advanced CKD.

Introduction

Chronic kidney disease (CKD) is described as the gradual loss of kidney function over time. CKD progresses through five stages [1]. Previous reports reveal that chronic hepatitis C virus (HCV) infection is the most common chronic liver disease in patients with advanced CKD [2].

The prevalence varies worldwide, with a higher proportion of infected patients in developing countries than in developed nations [3, 4]. In Western countries, it has been estimated that almost 6% of patients with advanced CKD, who are on conservative therapy, are infected with HCV [5]. Approximately 4% to 70% of patients on hemodialysis (HD), and between 11% and 49% of kidney transplant (KTx) recipients are infected with HCV [6]. HCV infection is detected as a frequent cause of morbidity, mortality, and graft failure among patients on HD and kidney transplant (KTx) recipients [7–10].

In earlier studies, PEGylated interferon (Peg-IFN) monotherapy showed higher SVR rates (approximately 40%) compared to conventional interferon therapy (approximately 30%) in HCV-infected CKD patients [11]. The addition of ribavirin (RBV) did not result in higher SVR rates compared to regimens restricted to peg-IFN. Antiviral therapy with peg-IFN with or without RBV was not quite effective and was associated with several side effects, which raised concerns about its safety [12]. Interferon and RBV are associated with significant toxicity including anemia, depression, anxiety, and other psychiatric side effects [13–15]. As a result, the main limitation of interferon-based regimens is their high withdrawal rates due to side effects (26.9%) [12].

Sofosbuvir is classified as a superior direct-acting nucleotide polymerase inhibitor that inhibits HCV replication through inhibition of NS5B RNA polymerase, which regulates the chronic HCV infection. This drug is metabolized in vivo into its active intracellular metabolite GS-461203 and the pharmacologically inactive form GS-331007. This active triphosphate of Sofosbuvir, GS-461203, targets the vastly conserved active site of the HCV-specific NS5B polymerase and acts as a nonobligatory chain terminator, an effect that is independent of the viral genotype [16]. The use of Sofosbuvir (400 mg/day) leads to drastically increased level of inactive metabolite GS331007 in patients with e-GFR < 30 mL/min/1.73 m^2, which raises concerns about the accumulation of GS331007 in patients with advanced CKD, possibly leading to toxicity as GS331007 is mostly eliminated by kidneys [17, 18]. The effective and safe dose of Sofosbuvir in advanced CKD patients is thus not established. Still, existing evidence on usage of Sofosbuvir in patients with e-GFR< 30 ml/min/1.73 m^2 is accumulating [19].

In a recent systematic review, the safety and efficacy of Sofosbuvir was explored among patients on HD [20] and results are quite similar to the results of the current study. However, there is a very important difference between the two studies. In our study, we included patients with eGFR<30 ml/min/1.73 m^2 and our search was not confined to patients on HD. This difference is quite important as the risk of toxic metabolite accumulation in patients with advanced CKD and not necessarily on HD may be even higher than patients on HD. We also excluded studies on acute HCV and studies on patients with HBV and HIV co-infection and we conducted subgroup and sensitivity analyses. Thus, in this updated systematic review and meta-analysis we used the currently available evidence to evaluate the antiviral efficacy of SOF-based therapy in combination with other direct acting antivirals (DAA) in advanced CKD patients infected chronically with HCV.

Materials and methods

We performed this systematic review to identify studies on Sofosbuvir-based antiviral therapy among HCV-infected patients with advanced CKD. This study was conducted in accordance with preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [21].

Search strategy

For systematic literature search, we used several international databases including PubMed/ Medline, Web of sciences, Scopus and CENTERAL on the Cochrane library from January 1st,

2013 (the year Sofosbuvir was approved for medical use) up to June 26th, 2020. The search strategy was based on a combination of key words from medical subject headings (Mesh) and free texts including "(dialysis OR hemodialysis OR end stage renal disease OR chronic kidney failure OR chronic kidney disease OR severe renal impairment) AND (Sofosbuvir OR N5B polymerase OR direct-acting antiviral). The details of our search strategy are presented in the S1 Appendix in S1 File. Finally, to avoid missing any relevant evidence, we reviewed the reference list of all included studies.

Study selection

After literature search by two independent reviewers (Kh M and S M), results of the initial search were incorporated into the reference manager software, duplicates were removed, and the two reviewers screened the studies by title, abstract, and full text independently and included or excluded them based on defined eligibility criteria.

Eligibility criteria

All studies would be eligible if they were published in full English and reported the efficacy and safety profiles of Sofosbuvir-based regimen for treatment-naive chronic HCV-infected patients (aged $\geq$ 18 years) with advanced CKD, defined as e-GFR $\leq$ 30 ml/min per 1.73 m^2 or being on dialysis. Studies on all HCV genotypes were included. Outcomes of interest were SVR rates at 12 or 24 weeks after the end of treatment. Studies were excluded if there was no sufficient data to calculate SVR12 or SVR24 rate and if HCV-infected patients were co-infected with other viral infections such as hepatitis B and HIV/AIDS.

Quality assessment

To assess the quality of included studies we used Newcastle—Ottawa quality assessment scale for cohort studies, which comprised three sections as follow: 1. Selection, 2. Comparability, and 3. Outcome [22]. Therefore, studies with cumulative score equal to 7 or more were classified as high quality studies (n = 6) and studies with cumulative scores between 4 and 6 were defined as fair quality studies (n = 21). Two reviewers (Kh M and S M) independently assessed the quality of each study. In order to explore the agreement between the two reviewers, we used Kappa statistics (Weighted kappa = 87%). Disagreements between the reviewers were resolved through discussions, or the final decision was made based on the opinion of the third reviewer (SM).

Data extraction

To extract the relevant data, two reviewers (Kh M and S M) independently used a pre-specified data extraction sheet in Microsoft Excel, which consisted of the following variables: name of the first author, year of publication, time of the study, country, study design, number of patients, mean age, sex distribution, baseline HCV RNA level, cirrhosis diagnosis, treatment strategy, doses of drugs and duration of treatment, the rate of SVR12 and/or SVR24, side effects, and mortality rate.

Statistical analysis

To investigate the between study heterogeneity we used I^2 index and chi-squared test at the 5% significance level (p <0.05). A random effects model was used to pool the SVR12 rate. We used metaprop command to estimate the exact binomial and score-test-based confidence intervals for proportions near boundaries (i.e., near 100% or zero) [23]. We also conducted

subgroup analysis and meta-regression by treatment strategy, dose of Sofosbuvir, diagnosis of cirrhosis, country of origin, and age. In this study, publication bias was not assessed, as the SVR rate is a proportion, is always a positive number, and the asymmetry in the funnel plot is not due to publication bias. This meta-analysis was performed in Stata 11 (StataCorp, College Station, TX, USA).

Results

Study characteristics

Our final systematic search yielded 27 relevant articles based on the eligibility criteria and we included these studies in our systematic review and meta-analyses (Fig 1). These studies were conducted in 10 countries, comprising 6 studies in the USA, 10 in India, 2 in France, 2 in Pakistan and single studies in Austria, Czech Republic, Iran, Korea, Egypt, and Brazil (Table 1). Detailed study characteristics are demonstrated in S1 Table in S1 File. The included studies contained extractable data on 1464 patients, among whom 809 were males and 655 were females. The mean age of all enrolled patients was 48.6±11 year. We included all articles that used Sofosbuvir-based therapies, and the enrollment period of these patients ranged from 2013 to 2020. All patients in 22 studies received full dose Sofosbuvir (400 mg) daily, while patients in 5 studies received half dose (200mg) Sofosbuvir daily. In all of the studies, Sofosbuvir was used in combination with other direct-acting antivirals (DAAs). Among all patients enrolled in the included studies, only 274 patients were cirrhotic. Characteristics of included studies are demonstrated in Table 1.

Heterogeneity

The between study heterogeneity based on I^2 index (P = 0.00, I^2 = 56.1%) was substantial.

Pooled SVR rate

Based on the random effects model, the pooled SVR12 and 24 rates were 97% (95% CI: 95–99) and 95% (89–99) respectively in our meta-analysis (Fig 2 and S1 Fig in S1 File).

Subgroup analysis

According to the results of subgroup analysis in Table 2, the pooled SVR12 rates were 98% (96–100) and 94% (90–97) in patients under 60 and over 60 years old respectively (S2 Fig in S1 File). The pooled SVR12 rate was 98% (91–100) in patients with cirrhosis and 100% (98–100) in non-cirrhotic patients (Fig 3). In subgroup analysis based on Sofosbuvir dose, the pooled SVR12 rate was 97% (94–99) in studies using full dose regimen (400 mg), and 99% (91–100) in studies using half dose (200mg) regimen (Fig 4). Results sub-grouped by region of study are presented in S3 Fig in S1 File showing lower SVR12 rates in Europe [95% (89–100)]. Fig 5 demonstrates the pooled SVR12 rate sub-grouped based on being treated only with Sofobuvir [99% (98–100)] or its combination with RBV [99% (95–100)]. We additionally defined subgroups by treatment strategy such as the result of the pooled SVR12 rate in 19 studies in which Sofosbuvir was used in combination with Daclatasvir [97% (94–99)], Simeprevir [99% (94–100)], and Ledipasvir [100% (100–100)]. Detailed results are reported in Fig 6. Table 2 demonstrates the summary of all sub-group analyses.

Safety

Severe adverse events (SAE) were reported in 6 studies (S4 Fig in S1 File). The pooled incidence of SAE was 0.11 (0.04–0.19), and the incidence of SAE in patients who received full dose SOF compared to half dose were 0.14 (0.04–0.28) vs. 0.06 (0.01–0.15). Mortality was reported in 11 studies, and none of them were due to treatment (S5 Fig in S1 File). Therefore, the

Fig 1. PRISMA flowchart showing different phases of selecting relevant publications.

estimated pooled mortality rate was 0.04 (0.01–0.09). In eight studies the discontinuation rate was reported and the pooled rate was 0.04 (0.00–0.11). (S6 Fig and S2 Table in S1 File)

Meta-regression analysis

The results of meta-regression analysis are shown in Table 3. There was a significant association between age (P = 0.03, β = 13.4) and country (P = 0.02, β = -18.1) and the pooled SVR12

Table 1. Study characteristics included in meta-analysis of SVR12 rate among HCV-infected patient with advanced chronic kidney disease.

First author/ year	Country	No. of patients	Recruitment period	Mean Age (SD)	Cirrhosis N (%)	No. of patient on dialysis/Total patient	SVR12	SVR24	NOS score
Taneja 2018 [24]	India	65	2016	49 (13)	21 (32.3%)	(54/65)	100	–	6
Surendra 2018 [25]	India	19	2016	44	0	(19/19)	100	–	6
Manoj 2018 [26]	India	71	2015–2017	42	17 (23.9%)	(11/71)	100	98.5	6
Akhil 2018 [16]	India	22	2015–2016	49.8	0	(22/22)	100	–	6
Sperl 2017 [27]	Czech Republic	6	2015–2016	39	2 (33.3%)	(6/6)	100	–	5
Dumortier 2017 [28]	France	50	2013–2015	60.5 (7.5)	0	(35/50)	86	–	6
Cox-North 2017 [29]	USA	29	2014–2016	–	13 (44.8%)	(0/29)	97	–	6
Choudhary 2017 [30]	India	16	2015–2016	45 (12)	2 (12.5%)	(16/16)	80	–	6
Aggarwal 2017 [31]	USA	14	–	61 (4.9)	12 (85.7%)	(14/14)	92.8	–	6
Agarwal 2017 [32]	India	62	2015–2016	33.8 (10.2)	3 (4.8%)	(62/62)	95.2	–	6
Singh 2016 [33]	USA	8	2014–2015	56.8 (20)	3 (37%)	(8/8)	100	–	6
Saxena 2016 [34]	USA	18	–	$\geq$65	-	-	88	–	8
Nazario 2016 [35]	USA	17	–	57	8 (47%)	(17/17)	100	–	6
Desnoyer 2016 [36]	France	12	2014–2015	52	10 (83.4%)	(12/12)	83.3	100	6
Beinhardt 2016 [37]	Austria	10	–	50.6 (10.9)	4 (40%)	(10/10)	96	96	8
Hundemer 2015 [38]	USA	6	2014	60 (14)	3 (50%)	(6/6)	64	–	6
Goel 2018 [39]	India	41	2015–2017	41	5 (12%)	(41/41)	90.2	–	6
Gupta 2018 [40]	India	7	2015–2016	48.8 ± 14.5	2 (28.6%)	(7/7)	100	–	6
Mehta 2018 [41]	India	38	2016	49.5	–	(26/26)	100 92.3	–	6
Borgia 2019 [42]	Canada, the United Kingdom, Spain, Israel, New Zealand, and Australia	59	2017–2018	60	17 (29%)	(59/59)	95	–	6
Poustchi 2020 [43]	Iran	103	2017–2018	50.3±13.5	39 (37.9%)	(75/103)	100	–	6
Eletreby 2020 [44]	Egypt	579	2014–2018	52	107 (11%)	10/579	96.7	–	8
Debnath 2020 [45]	India	18	2017–2018	39.4 ± 8.3	0	18/18	100	–	6
Michels 2020 [46]	Brazil	34	2016–2017	60.7±10.4	0	34/34	99.3	97.1	8
Cheema 2019 [47]	Pakistan	18	2017–2018	47.2±14.1	4 (22.2%)	18/18	83.3	83.3	8
Mandhwani 2020 [48]	Pakistan	133	2016–2018	31.9 ± 9.8	0	133/133	96.9	–	8
Seo 2020 [49]	Korea	9	2017–2018	59.9	2 (22.2%)	9/9	100	–	6

**Fig 2. Forest plot of the pooled SVR12 rate in HCV-infected patients with advanced chronic kidney disease.**

rate in the univariable model, which disappeared in the multivariable model. None of the variables of cirrhosis diagnosis, treatment strategy, and dose of treatment had significant association with the pooled SVR12 rate, neither in the univariable model nor in the multivariable meta-regression model.

Table 2. Results of subgroup analysis for estimating the pooled SVR12 rate in HCV-infected patients with advanced CKD.

	Title	Subgroup	Number of included studies	SVR12	95%CI	I^2 (P)
1	Treatment strategy	SOF+DCV	19	97%	(94–99)	53.6% (P = 0.00)
		SOF+SMV	9	99%	(94–100)	0.00 (P = 0.83)
		SOF+LDV	6	100%	(100–100)	0.00 (P = 0.99)
		SOF+RBV	8	97%	(83–100)	57.6% (P = 0.02)
		SOF+DCV +RBV	3	97%	(95–99)	0.00 (P = 0)
		SOF+PEG+RBV	3	96%	(79–100)	0.00 (P = 0)
2	Type of combination	Only SOF-based	27	99%	(98–100)	29.5% (P = 0.06)
		SOF-based + RBV	11	99%	(95–100)	51.8% (P = 0.01)
3	Dose of treatment	Full dose (400 mg)	22	97%	(94–99)	58.4% (P = 0.00)
		Half dose (200 mg)	5	99%	(91–100)	53.7% (P = 0.07)
3	Diagnosis of cirrhosis	Cirrhotic	12	98%	(91–100)	54.7% (P = 0.01)
		Non-Cirrhotic	19	100%	(98–100)	38.7% (P = 0.04)
4	Age group	<60 year	19	98%	(96–100)	60.1% (P = 0.00)
		>60 year	8	94%	(90–97)	0.00 (P = 0.57)
5	Region	America	7	96%	(91–100)	16.1% (P = 0.31)
		Asia	15	98%	(94–100)	68.7% (P = 0.00)
		Europe	4	95%	(89–100)	0.00 (0.5)

†SVR = Sustained viralogic response. RBV = Ribavirin. SOF = Sofosbuvir. DCV = Daclatasvir. LDV = Ledipasvir. SMV = Simeprevir.

Sensitivity analysis

To assess the effect of all studies on the pooled SVR12 rate, we used sensitivity analyses. In each step, we excluded one of the total of 27 studies and calculated the pooled SVR12 rate across the remaining 26 studies. Thus, we performed 27 sensitivity analyses and we made 27 different estimates of SVR12 upon exclusion of each study in each step. The highest and lowest estimates after excluding the studies by Dumortier [28] and Poustchi [43] were 98.9% (90.8–100) and 95.3% (91.1–100) respectively. So the pooled SVR12 rate was stable across studies. Our results are actually robust and don't depend on the choice of included studies.

Discussion

HCV-infected patients with advanced CKD form a susceptible population that can be treated with a combination of Sofosbuvir-based regimen and antiviral therapy. We included 27 relevant studies, comprising 1464 patients in our meta-analysis. The pooled SVR12 rate was 97%, which was an acceptable outcome.

The endorsement of Sofosbuvir-based regimen was a major advance in treatment of HCV-infected patients with stage 4–5 of CKD. Efficacy and safety profile concurs with high rates of SVR12-24 with few side effects.

In the systematic review conducted by Li M et al in 2019, the pooled SVR12/24 rate (97.1%) achieved by the SOF-based regimen was compatible with the results of our meta-analysis [50]. Also in the study conducted in 2016 by Li T et al [51], the reported SVR12 rate of DAAs-based regimens was 93.2%, which was lower compared to the result of our study as we focused only on Sofosbuvir-based regimen. In comparison with studies that included non-SOF-based therapies, our study revealed higher SVR12 rates and better tolerability following SOF-based therapy in HCV-infected patients with advanced CKD.

To assess the safety of SOF-based therapy, we computed the pooled discontinuation rate due to adverse events, which was just 4%. The low estimate reveals the satisfactory outcome of

Fig 3. Forest plot of the pooled SVR12 rate in HCV-infected patients with advanced CKD sub-grouped based on diagnosis of cirrhosis.

Study	ES (95% CI)	% Weight
Full dose		
Hundemer (2015)	0.67 (0.22, 0.96)	1.33
Desnoyer (2016)	0.83 (0.52, 0.98)	2.24
Beinhardt (2016)	0.90 (0.55, 1.00)	1.96
Singh (2016)	1.00 (0.63, 1.00)	1.66
Nazario (2016)	1.00 (0.80, 1.00)	2.84
Saxena (2016)	0.88 (0.64, 0.99)	2.84
Dumortier (2017)	0.86 (0.73, 0.94)	5.07
Choudhary (2017)	0.80 (0.44, 0.97)	1.96
Cox–North (2017)	0.97 (0.82, 1.00)	3.91
Agarwal (2017)	0.95 (0.87, 0.99)	5.50
Manoj (2018)	1.00 (0.95, 1.00)	5.77
Mehta (2018)	0.87 (0.72, 0.96)	4.49
Akhil (2018)	1.00 (0.85, 1.00)	3.34
Surendra (2018)	1.00 (0.82, 1.00)	3.05
Borgia (2019)	0.95 (0.86, 0.99)	5.41
Cheema (2020)	0.83 (0.59, 0.96)	2.95
Michels (2020)	0.97 (0.85, 1.00)	4.25
Seo (2020)	1.00 (0.66, 1.00)	1.82
Eletreby (2020)	0.97 (0.95, 0.98)	8.15
Debnath (2020)	1.00 (0.81, 1.00)	2.95
Mandhwani (2020)	0.97 (0.92, 0.99)	6.83
Poustchi (2020)	1.00 (0.96, 1.00)	6.28
Subtotal (I^2 = 58.49%, p = 0.00)	0.97 (0.94, 0.99)	84.60
Low dose		
Sperl (2017)	1.00 (0.54, 1.00)	1.33
Aggarwal (2017)	0.93 (0.66, 1.00)	2.50
Taneja (2018)	1.00 (0.94, 1.00)	5.60
Goel (2018)	0.90 (0.77, 0.97)	4.65
Gupta (2018)	1.00 (0.54, 1.00)	1.33
Subtotal (I^2 = 53.71%, p = 0.07)	0.99 (0.91, 1.00)	15.40
Heterogeneity between groups: p = 0.835		
Overall (I^2 = 56.17%, p = 0.00);	0.97 (0.95, 0.99)	100.00

Fig 4. Forest plot of the pooled SVR12 rate in HCV-infected patient with advanced CKD sub-grouped by SOF-based regimen dose.

| Study	ES (95% CI)	% Weight
SOF−based		
Hundemer 3 (2015)	0.67 (0.09, 0.99)	0.49
Singh 3 (2016)	1.00 (0.40, 1.00)	0.62
Desnoyer 2 (2016)	1.00 (0.03, 1.00)	0.22
Desnoyer 1 (2016)	0.78 (0.40, 0.97)	1.20
Beinhardt 1 (2016)	1.00 (0.40, 1.00)	0.62
Beinhardt 3 (2016)	1.00 (0.16, 1.00)	0.36
Singh 3 (2016)	1.00 (0.40, 1.00)	0.62
Desnoyer 3 (2016)	1.00 (0.16, 1.00)	0.36
Nazario 3 (2016)	1.00 (0.80, 1.00)	1.96
Agarwal 1 (2017)	0.95 (0.76, 1.00)	2.28
Cox−North 1 (2017)	1.00 (0.54, 1.00)	0.86
Dumortier 1 (2017)	0.86 (0.73, 0.94)	3.84
Cox−North 2 (2017)	1.00 (0.81, 1.00)	2.04
Choudhary 1 (2017)	1.00 (0.59, 1.00)	0.98
Sperl 1 (2017)	1.00 (0.54, 1.00)	0.86
Aggarwal 3 (2017)	0.93 (0.66, 1.00)	1.69
Akhil 2 (2018)	1.00 (0.29, 1.00)	0.49
Surendra 2 (2018)	1.00 (0.82, 1.00)	2.12
Mehta 2 (2018)	1.00 (0.74, 1.00)	1.51
Manoj 2 (2018)	1.00 (0.87, 1.00)	2.63
Mehta 1 (2018)	0.92 (0.64, 1.00)	1.60
Mehta 1 (2018)	0.69 (0.39, 0.91)	1.60
Manoj 1 (2018)	1.00 (0.82, 1.00)	2.12
Taneja 1 (2018)	1.00 (0.94, 1.00)	4.35
Goel 1 (2018)	0.90 (0.77, 0.97)	3.46
Gupta 1 (2018)	1.00 (0.54, 1.00)	0.86
Cheema 1 (2019)	0.83 (0.59, 0.96)	2.04
Eletreby 1 (2019)	0.97 (0.94, 0.98)	6.83
Eletreby 3 (2019)	0.93 (0.80, 0.98)	3.46
Debnath 2 (2020)	1.00 (0.75, 1.00)	1.60
Debnath 1 (2020)	1.00 (0.48, 1.00)	0.74
Poustchi 1 (2020)	0.91 (0.84, 0.96)	5.21
Mandhwani 1 (2020)	0.97 (0.92, 0.99)	5.64
Michels 3 (2020)	1.00 (0.63, 1.00)	1.09
Michels 1 (2020)	1.00 (0.86, 1.00)	2.56
Subtotal (I^2 = 29.25%, p = 0.06)	0.99 (0.98, 1.00)	68.89
SOF−based+RBV		
Hundemer 4 (2015)	0.67 (0.09, 0.99)	0.49
Desnoyer 4 (2016)	1.00 (0.03, 1.00)	0.22
Agarwal 4 (2017)	0.95 (0.83, 0.99)	3.46
Cox−North 5 (2017)	0.97 (0.82, 1.00)	2.82
Choudhary 6 (2017)	0.75 (0.35, 0.97)	1.09
Akhil 4 (2018)	0.73 (0.50, 0.89)	2.35
Manoj 4 (2018)	1.00 (0.87, 1.00)	2.63
Gupta 4 (2018)	1.00 (0.03, 1.00)	0.22
Eletreby 5 (2019)	0.98 (0.94, 0.99)	6.02
Eletreby 6 (2019)	1.00 (0.59, 1.00)	0.98
Eletreby 4 (2019)	0.67 (0.22, 0.96)	0.86
Mandhwani 6 (2020)	0.98 (0.91, 1.00)	4.20
Mandhwani 5 (2020)	0.96 (0.88, 0.99)	4.58
Seo 4 (2020)	1.00 (0.66, 1.00)	1.20
Subtotal (I^2 = 51.81%, p = 0.01)	0.99 (0.95, 1.00)	31.11
Heterogeneity between groups: p = 0.548		
Overall (I^2 = 36.03%, p = 0.01);	0.99 (0.98, 1.00)	100.00

Fig 5. Forest plot of the pooled SVR12 rate in HCV-infected patients with advanced CKD sub-grouped based on the use of SOF-based regimen with or without RBV. (1): SOF+DCV; (2): SOF+LDV; (3): SOF+SMV; (4): SOF+RBV; (5): SOF+DCV+RBV; (6): SOF+PEG+RBV.DCV = Daclatasvir. LDV = Ledipasvir. SMV = Simeprevir. RBV = Ribavirin.

SOF-based therapy. The discontinuation rate due to adverse events in the meta-analysis conducted by Li T [51] was 2.2%, which is compatible with our findings.

The pooled incidence of SAE due to SOF-based regimen in our study was 11%, which was similar to the study by Li T et al, in which the pooled SAE rate for DAA-based antiviral therapies in HCV/Stage 4–5 CKD patients was 12.1% [51]. Shehadeh et al also reported a 10% incidence for SAE, which is quite similar to our results [20].

Out of the 15 studies that reported anemia as an adverse event, RBV was used in combination with SOF-based therapy in 11 studies. Also in the meta-analysis conducted by Li T et al in 2016 [51], the most frequent adverse event was anemia, and in the systematic review by Li, M et al in 2019 [50], anemia was the most frequently reported adverse event and RBV was included in almost all of these studies. Shehadeh et al reported fatigue as the most frequent adverse event, followed by anemia. They consistently reported more prevalent anemia in treatment regimens containing RBV. Therefore, regimens containing RBV should be used with caution compared to RBV-free regimens due to high risk of anemia. In the study conducted by Manoj et al, 65.4% of patients who used SOF with RBV developed anemia [26].

Our subgroup analysis suggests that half dose SOF-based regimens are as effective as full dose regimens. The SVR12 rates are similar between half dose (99%) and full dose (97%) regimens. Furthermore, the SAE of half dose regimen (6%) is lower than the full dose treatment (14%). Similarly, Li M et al. (2019) found that both half dose and full dose regimens had considerably high SVR rate (97.1% vs. 96.2%). Li M et al (2019) also suggested lower dose of SOF as routine or usage of half dose once every 2 days with the same efficacy [50]. Shehadeh et al also showed higher efficacy with low-dose treatment [20].

The result of our meta-analysis also showed that the rate of SVR12 in patients who received Sofosbuvir-based treatment without RBV was 99%, which was similar to patients who received SOF with RBV (99%). As we mentioned previously, use of SOF-based treatment in combination with RBV should be used with caution since in addition to increasing the risk of anemia, it increases the discontinuation rate.

Additionally, in cirrhotic patients, the SVR12 rate was slightly lower than non-cirrhotic patients (98% vs. 100%). This finding of our study was similar to the results reported by Rezaee'i-Zavare et al. [52] They recommended that cirrhotic patients be treated with SOF-based regimen in combination with RBV for 12 weeks or without RBV for 24 weeks. Similar to the result of our study, they found that treatment of non-cirrhotic patient with SOF-based regimen without RBV for 12 weeks had acceptable outcomes [52].

Our study is a comprehensive systematic review and meta-analysis on efficacy of SOF-based therapies. We conducted subgroup analysis by combinations of Sofosbuvir with other DAAs regimens and we found out that this regimen is effective and safe in HCV-infected patients with advanced CKD. In addition, these combinations of SOF-based therapies with DAA regimens reduced the incidence of anemia caused by RBV [51].

Our study has certain limitations as well. Firstly, we observed a substantial heterogeneity that might be due to different sampling frames and sample size or different treatment strategies used in a variety of contexts. All included studies were observational without proper control groups. Additionally, almost all studies were conducted in the USA and India. Therefore, the findings of our study cannot be generalized to all populations.

Study	ES (95% CI)	% Weight
SOF+DCV		
Desnoyer (2016)	0.78 (0.40, 0.97)	1.23
Beinhardt (2016)	1.00 (0.40, 1.00)	0.63
Sperl (2017)	1.00 (0.54, 1.00)	0.88
Cox–North (2017)	1.00 (0.54, 1.00)	0.88
Dumortier (2017)	0.86 (0.73, 0.94)	3.89
Agarwal (2017)	0.95 (0.76, 1.00)	2.32
Choudhary (2017)	1.00 (0.59, 1.00)	1.00
Gupta (2018)	1.00 (0.54, 1.00)	0.88
Mehta (2018)	0.69 (0.39, 0.91)	1.64
Taneja (2018)	1.00 (0.94, 1.00)	4.40
Manoj (2018)	1.00 (0.82, 1.00)	2.17
Goel (2018)	0.90 (0.77, 0.97)	3.51
Mehta (2018)	0.92 (0.64, 1.00)	1.64
Eletreby (2019)	0.97 (0.94, 0.98)	6.83
Cheema (2019)	0.83 (0.59, 0.96)	2.08
Debnath (2020)	1.00 (0.48, 1.00)	0.76
Poustchi (2020)	0.91 (0.84, 0.96)	5.24
Mandhwani (2020)	0.97 (0.92, 0.99)	5.66
Michels (2020)	1.00 (0.86, 1.00)	2.61
Subtotal (I^2 = 53.62%, p = 0.00)	0.97 (0.94, 0.99)	48.29
SOF+DCV+RBV		
Cox–North (2017)	0.97 (0.82, 1.00)	2.87
Eletreby (2019)	0.98 (0.94, 0.99)	6.04
Mandhwani (2020)	0.96 (0.88, 0.99)	4.62
Subtotal (I^2 = .%, p = .)	0.97 (0.95, 0.99)	13.53
SOF+LDV		
Desnoyer (2016)	1.00 (0.03, 1.00)	0.22
Cox–North (2017)	1.00 (0.81, 1.00)	2.08
Surendra (2018)	1.00 (0.82, 1.00)	2.17
Akhil (2018)	1.00 (0.29, 1.00)	0.50
Manoj (2018)	1.00 (0.87, 1.00)	2.68
Debnath (2020)	1.00 (0.75, 1.00)	1.64
Subtotal (I^2 = 0.00%, p = 0.98)	1.00 (1.00, 1.00)	9.29
SOF+PEG+RBV		
Choudhary (2017)	0.75 (0.35, 0.97)	1.12
Eletreby (2019)	1.00 (0.59, 1.00)	1.00
Mandhwani (2020)	0.98 (0.91, 1.00)	4.25
Subtotal (I^2 = .%, p = .)	0.96 (0.79, 1.00)	6.37
SOF+RBV		
Hundemer (2015)	0.67 (0.09, 0.99)	0.50
Desnoyer (2016)	1.00 (0.03, 1.00)	0.22
Agarwal (2017)	0.95 (0.83, 0.99)	3.51
Gupta (2018)	1.00 (0.03, 1.00)	0.22
Manoj (2018)	1.00 (0.87, 1.00)	2.68
Akhil (2018)	0.73 (0.50, 0.89)	2.40
Eletreby (2019)	0.67 (0.22, 0.96)	0.88
Seo (2020)	1.00 (0.66, 1.00)	1.23
Subtotal (I^2 = 57.67%, p = 0.02)	0.97 (0.83, 1.00)	11.65
SOF+SMV		
Hundemer (2015)	0.67 (0.09, 0.99)	0.50
Singh (2016)	1.00 (0.40, 1.00)	0.63
Desnoyer (2016)	1.00 (0.16, 1.00)	0.37
Nazario (2016)	1.00 (0.80, 1.00)	2.00
Beinhardt (2016)	1.00 (0.16, 1.00)	0.37
Singh (2016)	1.00 (0.40, 1.00)	0.63
Aggarwal (2017)	0.93 (0.66, 1.00)	1.73
Eletreby (2019)	0.93 (0.80, 0.98)	3.51
Michels (2020)	1.00 (0.63, 1.00)	1.12
Subtotal (I^2 = 0.00%, p = 0.83)	0.99 (0.94, 1.00)	10.87
Heterogeneity between groups: p = 0.114		
Overall (I^2 = 37.12%, p = 0.01);	0.99 (0.98, 1.00)	100.00

Fig 6. Forest plot of the pooled SVR12 rate in HCV-infected patients with advanced CKD by treatment strategy. DCV = Daclatasvir. LDV = Ledipasvir. SMV = Simeprevir. RBV = Ribavirin.

https://doi.org/10.1371/journal.pone.0246594.g006

Table 3. Meta-regression analysis for the effect of suspected variables on the pooled SVR12 rate in HCV-infected patients with advanced chronic kidney disease.

Variable		Univariable Model			Multivariable Model	
	β	SE	P Value	β	SE	P Value
Age	18.1	7.4	0.02	10.1	9.7	0.30
Country	-19.3	7.5	0.01	-12.6	9.9	0.21
Cirrhosis diagnosis	6.1	6.4	0.34	3.2	5.3	0.55
treatment strategy	-4.2	9.5	0.65	-3.1	10.1	0.75
dose of drugs	4.4	9.7	0.64	3.4	10.3	0.74

https://doi.org/10.1371/journal.pone.0246594.t003

Conclusions

The results of this study showed satisfactory and novel findings regarding the usage of half dose SOF-based regimen in HCV-infected patients with advanced CKD. We demonstrated that the use of SOF-based therapy in full or low dose has considerable efficacy in cirrhotic and non-cirrhotic patients. The results of our study have important policy implications as well. The massive production of Sofosbuvir can be a cost-effective strategy to eliminate chronic HCV or at least prevent premature death in advanced CKD patients infected with hepatitis C virus.

Supporting information

S1 Checklist. PRISMA 2009 checklist.
(DOC)

S1 File.
(PDF)

Author Contributions

Conceptualization: Sara Majd Jabbari, Sadaf G. Sepanlou.

Data curation: Sara Majd Jabbari, Khadije Maajani.

Formal analysis: Khadije Maajani, Sadaf G. Sepanlou.

Supervision: Sadaf G. Sepanlou.

Writing – original draft: Sara Majd Jabbari, Khadije Maajani, Shahin Merat.

Writing – review & editing: Shahin Merat, Hossein Poustchi, Sadaf G. Sepanlou.

References

1. Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives—a position statement from Kidney Disease Improving Global Outcomes. Kidney international. 2007; 72(3):247–59. Epub 2007/06/15. https://doi.org/10.1038/sj.ki.5002343 PMID: 17568785.

2. Morales JM, Kamar N, Rostaing L. Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy. Contrib Nephrol. 2012; 176:10–23. Epub 2012/02/09. https://doi.org/10.1159/000333772 PMID: 22310777.

3. Covic A, Iancu L, Apetrei C, Scripcaru D, Volovat C, Mititiuc I, et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant. 1999; 14(1):40–5. Epub 1999/03/03. https://doi.org/10.1093/ndt/14.1.40 PMID: 10052474.

4. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol. 2007; 18(5):1584–93. Epub 2007/04/13. https://doi.org/10.1681/ASN.2006070736 PMID: 17429053.

5. Li Cavoli G, Ferrantelli A, Bono L, Tortorici C, Giammarresi C, Zagarrigo C, et al. Incidence of hepatitis C virus infection in patients with chronic kidney disease on conservative therapy. Int J Infect Dis. 2011; 15(8):e514–6. Epub 2011/06/18. https://doi.org/10.1016/j.ijid.2011.04.001 PMID: 21680217.

6. Burra P, Rodríguez-Castro KI, Marchini F, Bonfante L, Furian L, Ferrarese A, et al. Hepatitis C virus infection in end-stage renal disease and kidney transplantation. Transpl Int. 2014; 27(9):877–91. Epub 2014/05/24. https://doi.org/10.1111/tri.12360 PMID: 24853721.

7. Butt AA, Skanderson M, McGinnis KA, Ahuja T, Bryce CL, Barnato AE, et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J Viral Hepat. 2007; 14(10):688–96. Epub 2007/09/19. https://doi.org/10.1111/j.1365-2893.2007.00853.x PMID: 17875003.

8. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007; 14(10):697–703. Epub 2007/09/19. https://doi.org/10.1111/j.1365-2893.2007.00868.x PMID: 17875004.

9. Legendre C, Garrigue V, Le Bihan C, Mamzer-Bruneel MF, Chaix ML, Landais P, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation. 1998; 65 (5):667–70. Epub 1998/04/01. https://doi.org/10.1097/00007890-199803150-00011 PMID: 9521201.

10. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000; 11(10):1896–902. Epub 2000/09/27. PMID: 11004221.

11. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney international Supplement. 2008;(109):S1-99. Epub 2008/05/03. https://doi.org/10.1038/ki.2008.81 PMID: 18382440.

12. Espinosa M, Hernàndez J, Arenas MD, Carnicer F, Caramelo C, Fabrizi F. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population. Kidney Blood Press Res. 2015; 40 (3):258–65. Epub 2015/05/23. https://doi.org/10.1159/000368501 PMID: 25997572.

13. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339(21):1485–92. Epub 1998/11/20. https://doi.org/10.1056/NEJM199811193392101 PMID: 9819446.

14. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998; 352(9138):1426–32. Epub 1998/11/10. https://doi.org/10.1016/s0140-6736(98)07124-4 PMID: 9807989.

15. Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, et al. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology. 2000; 32(4 Pt 1):835–41. Epub 2000/09/26. https://doi.org/10.1053/jhep.2000.17740 PMID: 11003631; PubMed Central PMCID: PMC7165866.

16. Akhil MS, Kirushnan B, Martin M, Arumugam K, Ganesh Prasad NK, Ravichandran R. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. Nephrology (Carlton, Vic). 2018; 23(5):446–52. Epub 2017/03/25. https://doi.org/10.1111/nep.13050 PMID: 28339162.

17. Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hepatol Int. 2015; 9 (2):161–73. Epub 2015/03/20. https://doi.org/10.1007/s12072-014-9606-9 PMID: 25788194.

18. Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. Drug safety. 2016; 39(7):589–611. Epub 2016/04/22. https://doi.org/10.1007/s40264-016-0420-2 PMID: 27098247; PubMed Central PMCID: PMC4912979.

19. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62(3):932–54. Epub 2015/06/26. https://doi.org/10.1002/hep.27950 PMID: 26111063.

20. Shehadeh F, Kalligeros M, Byrd K, Shemin D, Mylonakis E, Martin P, et al. Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis. Scientific reports. 2020; 10(1):14332. Epub 2020/09/02. https://doi.org/10.1038/s41598-020-71205-5 PMID: 32868869; PubMed Central PMCID: PMC7459301 declare no conflicts of interest.

21. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for
     systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4(1):1.
     Epub 2015/01/03. https://doi.org/10.1186/2046-4053-4-1 PMID: 25554246; PubMed Central PMCID:
     PMC4320440.

22. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale
     (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014. Available from:
     http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

23. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data.
     Archives of public health = Archives belges de sante publique. 2014; 72(1):39. Epub 2014/01/01.
     https://doi.org/10.1186/2049-3258-72-39 PMID: 25810908; PubMed Central PMCID: PMC4373114.

24. Taneja S, Duseja A, De A, Mehta M, Ramachandran R, Kumar V, et al. Low-Dose Sofosbuvir Is Safe
     and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage
     Renal Disease. Digestive diseases and sciences. 2018; 63(5):1334–40. Epub 2018/02/28. https://doi.
     org/10.1007/s10620-018-4979-6 PMID: 29484572.

25. Surendra M, Raju SB, Sridhar N, Vijay Kiran B, Rajesh G, Anvesh G, et al. Ledipasvir and Sofosbuvir
     for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational
     study. Hemodialysis international International Symposium on Home Hemodialysis. 2018; 22(2):217–
     21. Epub 2017/10/04. https://doi.org/10.1111/hdi.12604 PMID: 28972699.

26. Manoj K, Nayak SL, Gupta E, Kataria A, Sarin SK. Generic sofosbuvir-based direct-acting antivirals in
     hepatitis C virus-infected patients with chronic kidney disease. Liver international: official journal of the
     International Association for the Study of the Liver. 2018; 38(12):2137–48. Epub 2018/04/21. https://
     doi.org/10.1111/liv.13863 PMID: 29676846.

27. Sperl J, Frankova S, Kreidlova M, Merta D, Tothova M, Spicak J. Combination of sofosbuvir and dacla-
     tasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance
     hemodialysis. Therapeutics and clinical risk management. 2017; 13:733–8. Epub 2017/08/10. https://
     doi.org/10.2147/TCRM.S133983 PMID: 28790832; PubMed Central PMCID: PMC5488764.

28. Dumortier J, Bailly F, Pageaux GP, Vallet-Pichard A, Radenne S, Habersetzer F, et al. Sofosbuvir-
     based antiviral therapy in hepatitis C virus patients with severe renal failure. Nephrol Dial Transplant.
     2017; 32(12):2065–71. Epub 2016/11/01. https://doi.org/10.1093/ndt/gfw348 PMID: 27760839.

29. Cox-North P, Hawkins KL, Rossiter ST, Hawley MN, Bhattacharya R, Landis CS. Sofosbuvir-based reg-
     imens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatology communications.
     2017; 1(3):248–55. Epub 2018/02/07. https://doi.org/10.1002/hep4.1035 PMID: 29404457; PubMed
     Central PMCID: PMC5721450.

30. Choudhary NS, Kumar A, Bodh V, Bansal SB, Sharma R, Jain M, et al. Efficacy and safety of sofosbu-
     vir-based regimens in chronic hepatitis C patients on dialysis. Indian journal of gastroenterology: official
     journal of the Indian Society of Gastroenterology. 2017; 36(2):113–6. Epub 2017/03/11. https://doi.org/
     10.1007/s12664-017-0735-7 PMID: 28281085.

31. Aggarwal A, Yoo ER, Perumpail RB, Cholankeril G, Kumari R, Daugherty TJ, et al. Sofosbuvir Use in
     the Setting of End-stage Renal Disease: A Single Center Experience. Journal of clinical and transla-
     tional hepatology. 2017; 5(1):23–6. Epub 2017/05/17. https://doi.org/10.14218/JCTH.2016.00060
     PMID: 28507922; PubMed Central PMCID: PMC5411352.

32. Agarwal SK, Bagchi S, Yadav RK. Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-
     based Regimen. Kidney Int Rep. 2017; 2(5):831–5. Epub 2017/12/23. https://doi.org/10.1016/j.ekir.
     2017.04.003 PMID: 29270489; PubMed Central PMCID: PMC5733818.

33. Singh T, Guirguis J, Anthony S, Rivas J, Hanouneh IA, Alkhouri N. Sofosbuvir-based treatment is safe
     and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
     Liver international: official journal of the International Association for the Study of the Liver. 2016; 36
     (6):802–6. Epub 2016/01/30. https://doi.org/10.1111/liv.13078 PMID: 26824848.

34. Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, et al. Safety and efficacy of sofosbu-
     vir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver international:
     official journal of the International Association for the Study of the Liver. 2016; 36(6):807–16. Epub
     2016/03/01. https://doi.org/10.1111/liv.13102 PMID: 26923436; PubMed Central PMCID:
     PMC6453817.

35. Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with
     end-stage renal disease on haemodialysis or GFR< 30 ml/min. Liver International. 2016; 36(6):798–
     801. Epub 2015/11/20. https://doi.org/10.1111/liv.13025 PMID: 26583882.

36. Desnoyer A, Pospai D, Lê MP, Gervais A, Heurgué-Berlot A, Laradi A, et al. Pharmacokinetics, safety
     and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic
     hepatitis C. Journal of hepatology. 2016; 65(1):40–7. Epub 2016/03/10. https://doi.org/10.1016/j.jhep.
     2016.02.044 PMID: 26952005.

37. Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R, et al. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre-and postkidney transplantation setting. Transplant International. 2016; 29(9):999–1007. Epub 2016/05/21. https://doi.org/10.1111/tri.12799 PMID: 27203857.

38. Hundemer GL, Sise ME, Wisocky J, Ufere N, Friedman LS, Corey KE, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infectious Diseases. 2015; 47(12):924–9. https://doi.org/10.3109/23744235.2015.1078908 WOS:000361337300014. PMID: 26365684

39. Goel A, Bhadauria DS, Kaul A, Verma P, Mehrotra M, Gupta A, et al. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min. Nephrology. 2019; 24(3):316–21. Epub 2018/01/13. https://doi.org/10.1111/nep.13222 PMID: 29327401.

40. Gupta A, Arora P, Jain P. Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With End Stage Renal Disease on Hemodialysis: A Single Center Experience from India. J Clin Exp Hepatol. 2018; 8(2):116–20. Epub 2018/06/13. https://doi.org/10.1016/j.jceh.2017.10.001 PMID: 29892172; PubMed Central PMCID: PMC5992300.

41. Mehta R, Desai K, Kabrawala M, Nandwani S, Shah J, Desai N, et al. Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis. Indian Journal of Gastroenterology. 2018; 37(1):72–3. https://doi.org/10.1007/s12664-018-0833-1 PMID: 29430587

42. Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben–Ari Z, et al. Sofosbuvir/Velpatasvir for 12 Weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis. Journal of hepatology. 2019; 71(4):660–5. https://doi.org/10.1016/j.jhep.2019.05.028 Epub 2019 Jun 11. PMID: 31195062.

43. Poustchi H, Majd Jabbari S, Merat S, Sharifi AH, Shayesteh AA, Shayesteh E, et al. The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. J Gastroenterol Hepatol. 2020; 35(9):1590–4. Epub 2020/01/30. https://doi.org/10.1111/jgh.14994 PMID: 31994788.

44. Eletreby R, El-Serafy M, Anees M, Kasem G, Salama M, Elkhouly R, et al. Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Liver international: official journal of the International Association for the Study of the Liver. 2020; 40 (4):797–805. Epub 2019/12/21. https://doi.org/10.1111/liv.14299 PMID: 31858694.

45. Debnath P, Chandnani S, Rathi P, Nair S, Pawar V, Contractor Q. Combined Ns5a & Ns5b Nucleotide Inhibitor Therapy for Patients with Chronic Hepatitis C with Stage 5 Chronic Kidney Disease on Hemodialysis. Arq Gastroenterol. 2020; 57(1):39–44. Epub 2020/04/16. https://doi.org/10.1590/S0004-2803.202000000-08 PMID: 32294734.

46. Michels FBL, Amaral ACC, Carvalho-Filho RJ, Vieira GA, Souza A, Ferraz MLG. Hepatitis C Treatment of Renal Transplant and Chronic Kidney Disease Patients: Efficacy and Safety of Direct-Acting Antiviral Regimens Containing Sofosbuvir. Arq Gastroenterol. 2020; 57(1):45–9. Epub 2020/04/16. https://doi.org/10.1590/S0004-2803.202000000-09 PMID: 32294735.

47. Cheema SUR, Rehman MS, Hussain G, Cheema SS, Gilani N. Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial. BMC Nephrol. 2019; 20(1):438. Epub 2019/11/30. https://doi.org/10.1186/s12882-019-1631-4 PMID: 31779583; PubMed Central PMCID: PMC6883698.

48. Mandhwani R, Hanif FM, Lail G, Luck NH, Khalid MA, Ul Haque MM, et al. Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan. Gastroenterol Hepatol Bed Bench. 2020; 13(2):141–6. Epub 2020/04/21. PMID: 32308935; PubMed Central PMCID: PMC7149816.

49. Seo HY, Seo MS, Yoon SY, Choi JW, Ko SY. Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis. Korean J Intern Med. 2020; 35(3):559–65. Epub 2019/05/09. https://doi.org/10.3904/kjim.2018.338 PMID: 31064176; PubMed Central PMCID: PMC7214360.

50. Li M, Chen J, Fang Z, Li Y, Lin Q. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis. Virol J. 2019; 16(1):34. Epub 2019/03/16. https://doi.org/10.1186/s12985-019-1140-x PMID: 30871566; PubMed Central PMCID: PMC6419462.

51. Li T, Qu Y, Guo Y, Wang Y, Wang L. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4–5 chronic kidney disease: a meta-analysis. Liver international: official journal of the International Association for the Study of the Liver. 2017; 37(7):974–81. Epub 2016/12/13. https://doi.org/10.1111/liv.13336 PMID: 27943605.

52. Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi H. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. Ann Hepatol. 2017; 16(2):188–97. Epub 2017/02/25. https://doi.org/10.5604/16652681.1231562 PMID: 28233739.